Paul Peter joined Flagship Pioneering in October 2018. He is also CEO of Kintai Therapeutics, a Flagship Pioneering company.
Over a more than 25-year career in the life sciences, Paul-Peter has created and led multiple companies. He co-founded Arthrogen b.v. (Amsterdam, Netherlands) in 2005, where he was chief scientific officer until 2011. He was CEO and board member of Tempero Pharmaceuticals (Cambridge, MA) from 2012 until 2015, at which point he facilitated the company’s acquisition by GSK. From 2011 until 2017, Paul-Peter founded and served as senior vice president and head of the immuno-inflammation therapy area unit at GSK. Under Paul-Peter’s leadership, this unit brought more than 10 new mechanisms of action into the clinic and filed Benlysta s.c., which has been approved for the treatment of SLE. From 2016 until 2018, Paul-Peter was senior vice president of R&D pipeline, chief immunology officer, development leader, and co-chair of GSK’s scientific review board. He oversaw the creation of a new portfolio of medicines in oncology, with a focus on immuno-oncology, epigenetics, and cell and gene therapy. As chief immunology officer, he created the Immunology Network, an immunology platform underpinning all therapy areas at GSK.
Trained as a general internist, rheumatologist, and immunologist, Paul-Peter had held multiple professorships and has published extensively, with more than 550 papers in his name. He served as professor of medicine and chair of the department of clinical immunology and rheumatology at the Academic Medical Centre/University of Amsterdam for twelve years. He is a professor of medicine at the Amsterdam University Medical Center, honorary professor of rheumatology at Ghent University, and honorary senior visiting fellow at the University of Cambridge. He is a fellow of the Academy of Medical Sciences in the U.K.
Paul-Peter serves on several company and editorial boards. He is a co-founder of Sitryx Therapeutics. He is a current board member of Omega Therapeutics (Cambridge, Mass.), Sitryx Therapeutics (Oxford, UK), Levicept (London, UK), and he has also served on the board of directors of ViiV Healthcare and Galvani Bioelectronics. He is a member of the editorial board at Current Biotechnology and was previously the co-editor of Arthritis & Rheumatology.
Paul-Peter received his medical degree cum laude from the Free University in Amsterdam and his Ph.D. from Leiden University Medical Center.